JP2025500459A - バルプロ酸の新規類似体及びそれを用いた治療方法 - Google Patents

バルプロ酸の新規類似体及びそれを用いた治療方法 Download PDF

Info

Publication number
JP2025500459A
JP2025500459A JP2024538134A JP2024538134A JP2025500459A JP 2025500459 A JP2025500459 A JP 2025500459A JP 2024538134 A JP2024538134 A JP 2024538134A JP 2024538134 A JP2024538134 A JP 2024538134A JP 2025500459 A JP2025500459 A JP 2025500459A
Authority
JP
Japan
Prior art keywords
fibrosis
compound
pharmaceutical composition
compounds
subject
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2024538134A
Other languages
English (en)
Japanese (ja)
Other versions
JP2025500459A5 (https=
JPWO2023118846A5 (https=
Inventor
フェックス，トーマス
ファイヤソン セルヨー，ヨナス
Original Assignee
セレノ サイエンティフィク アクティエ ボラーグ
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by セレノ サイエンティフィク アクティエ ボラーグ filed Critical セレノ サイエンティフィク アクティエ ボラーグ
Publication of JP2025500459A publication Critical patent/JP2025500459A/ja
Publication of JP2025500459A5 publication Critical patent/JP2025500459A5/ja
Publication of JPWO2023118846A5 publication Critical patent/JPWO2023118846A5/ja
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C53/00—Saturated compounds having only one carboxyl group bound to an acyclic carbon atom or hydrogen
    • C07C53/126—Acids containing more than four carbon atoms
    • C07C53/128—Acids containing more than four carbon atoms the carboxylic group being bound to a carbon atom bound to at least two other carbon atoms, e.g. neo-acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B59/00—Introduction of isotopes of elements into organic compounds ; Labelled organic compounds per se
    • C07B59/001—Acyclic or carbocyclic compounds
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C51/00—Preparation of carboxylic acids or their salts, halides or anhydrides
    • C07C51/347—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups
    • C07C51/377—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups
    • C07C51/38—Preparation of carboxylic acids or their salts, halides or anhydrides by reactions not involving formation of carboxyl groups by splitting-off hydrogen or functional groups; by hydrogenolysis of functional groups by decarboxylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Psychiatry (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2024538134A 2021-12-20 2022-12-20 バルプロ酸の新規類似体及びそれを用いた治療方法 Pending JP2025500459A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB2118559.0 2021-12-20
GB2118559.0A GB2613900B (en) 2021-12-20 2021-12-20 Novel compounds and methods of use thereof
PCT/GB2022/053318 WO2023118846A1 (en) 2021-12-20 2022-12-20 Novel analogs of valproic acid and methods of medical treatment using the same

Publications (3)

Publication Number Publication Date
JP2025500459A true JP2025500459A (ja) 2025-01-09
JP2025500459A5 JP2025500459A5 (https=) 2025-11-26
JPWO2023118846A5 JPWO2023118846A5 (https=) 2025-11-26

Family

ID=84887257

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2024538134A Pending JP2025500459A (ja) 2021-12-20 2022-12-20 バルプロ酸の新規類似体及びそれを用いた治療方法

Country Status (11)

Country Link
US (1) US20250066282A1 (https=)
EP (1) EP4452917A1 (https=)
JP (1) JP2025500459A (https=)
KR (1) KR20240152301A (https=)
CN (1) CN118613464A (https=)
AU (1) AU2022422574A1 (https=)
CA (1) CA3242987A1 (https=)
GB (1) GB2613900B (https=)
IL (1) IL313669A (https=)
MX (1) MX2024007654A (https=)
WO (1) WO2023118846A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB2644641A (en) * 2024-09-24 2026-04-29 Cereno Scient Ab New methods
WO2026068561A1 (en) 2024-09-24 2026-04-02 Cereno Scientific Ab Valproic acid for use in treating pulmonary arterial hypertension
GB2644610A (en) * 2024-09-27 2026-04-22 Cereno Scient Ab New methods
WO2026068552A1 (en) 2024-09-24 2026-04-02 Cereno Scientific Ab Deuterated valproic acid compounds for use in treating pulmonary arterial hypertension

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20120071554A1 (en) * 2008-10-28 2012-03-22 Liu Julie F Deuterated 2-propylpentanoic acid compounds
US20100143507A1 (en) * 2008-12-09 2010-06-10 Auspex Pharmaceuticals, Inc. Carboxylic acid inhibitors of histone deacetylase, gaba transaminase and sodium channel
GB201417828D0 (en) * 2014-10-08 2014-11-19 Cereno Scient Ab New methods and compositions
RU2760304C2 (ru) * 2016-04-08 2021-11-23 Серено Сайентифик Аб Фармацевтические составы с отсроченным высвобождением, содержащие вальпроевую кислоту, и их применение

Also Published As

Publication number Publication date
GB2613900A (en) 2023-06-21
CN118613464A (zh) 2024-09-06
IL313669A (en) 2024-08-01
KR20240152301A (ko) 2024-10-21
CA3242987A1 (en) 2023-06-29
MX2024007654A (es) 2024-07-04
GB2613900B (en) 2024-01-17
AU2022422574A1 (en) 2024-07-18
EP4452917A1 (en) 2024-10-30
US20250066282A1 (en) 2025-02-27
WO2023118846A1 (en) 2023-06-29

Similar Documents

Publication Publication Date Title
JP2025500459A (ja) バルプロ酸の新規類似体及びそれを用いた治療方法
JP7744440B2 (ja) 薬学的に活性な化合物としてのレゾルシノール誘導体及びその調製の方法
JP4775259B2 (ja) アニリン誘導体
CN112047931B (zh) FXIa凝血因子抑制剂、其药物组合物和用途
WO2011118672A1 (ja) 血漿カリクレイン阻害剤
JP2025164962A (ja) ミトコンドリア病の治療のためのキノン類似体、ヒドロキノン類似体及びナフトキノン類似体
JP2010143937A (ja) 抗凝血薬として用いるクマリン誘導体
EA027451B1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и их применение
CN107207421A (zh) 新的三氟甲基丙酰胺衍生物
AU2021273632A1 (en) N-acylethanolamide derivatives and uses thereof
TW201619133A (zh) 新穎亞氨腈（ｉｍｉｎｏｎｉｔｒｉｌｅ）衍生物
PT1369419E (pt) Composto de n-fenilarilsulfonamida, fármaco contendo o composto como ingrediente activo, produtos intermédios para a produção do composto e processos para a produção do composto
JP5945227B2 (ja) Ａβ４２の生成を減少させる新規な組成物及びアルツハイマー病（ＡＤ）の治療におけるその使用
KR101061764B1 (ko) 신경보호효과를 가지는 피루베이트 유도체, 이의 제조방법 및 이를 포함하는 약제학적 조성물
FI115630B (fi) Menetelmä 4-(3-syaanifenyyli)-trifluorimetyyli-5-okso-1,4,5,6,7,8-heksahydrokinoliini-3-karboksyylihapon valmistamiseksi
JP2001517623A (ja) トロンビン阻害薬
CN100560568C (zh) 环酰亚胺类肽金属蛋白酶抑制剂及其应用
TW201700474A (zh) 新的５型磷酸二酯酶抑制劑及其醫藥應用
CN114685472B (zh) 多取代的尿嘧啶衍生物及其用途
CN117164566B (zh) 一种氧代哒嗪类化合物及其制备方法和用途
US20220098238A1 (en) Therapeutic compounds and methods
CN110759901A (zh) 四氢异喹啉类衍生物及其制备方法和用途
JP7458984B2 (ja) テトラヒドロイソキノリン系誘導体、その製造方法及び用途
JPH11503129A (ja) 新規の複素環化合物
WO2026068552A1 (en) Deuterated valproic acid compounds for use in treating pulmonary arterial hypertension

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20251117

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20251117